title: Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients.
abstract: BACKGROUND
  Acute rejection is an inherent risk of the withdrawal of steroids in renal allograft recipients. Mycophenolate mofetil is a potent immunosuppressant that, when given with cyclosporine (CsA), reduces the incidence of acute rejection and may facilitate discontinuation of steroids without increasing the risk of rejection.
  
  
  METHODS
  In an open pilot study, steroids were withdrawn from 26 adult cadaveric kidney transplant recipients. Corticosteroids were discontinued between 4 and 30 (mean 17) months after transplantation, and steroid-free follow-up ranged from 7 to 18 (mean 10) months.
  
  
  RESULTS
  Mean CsA doses, CsA blood levels, and serum creatinine at the time of steroid withdrawal and at last patient visit after cessation of steroids were 4.2+/-1.2 mg/kg/day and 3+/-0.8 mg/kg/day (P<0.001), 170+/-53 ng/ml and 113+/-34 ng/ml (P<0.001), and 133+/-36 microM/L and 130+/-37 microM/L (NS), respectively. No rejection episodes occurred after steroid withdrawal.
  
  
  CONCLUSIONS
  This open study shows that corticosteroids can be safely and successfully withdrawn from renal allograft recipients receiving CsA and mycophenolate mofetil.
authors.affiliation: Department of Nephrology, Hospital de Bellvitge, Ciutat Sanitaria i Universitaria de Bellvitge, University of Barcelona, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Grinyo
authors.forename: S
authors.initials: S
authors.lastname: Gil-Vernet
authors.forename: D
authors.initials: D
authors.lastname: Serón
authors.forename: J M
authors.initials: JM
authors.lastname: Cruzado
authors.forename: F
authors.initials: F
authors.lastname: Moreso
authors.forename: X
authors.initials: X
authors.lastname: Fulladosa
authors.forename: A M
authors.initials: AM
authors.lastname: Castelao
authors.forename: J
authors.initials: J
authors.lastname: Torras
authors.forename: L
authors.initials: L
authors.lastname: Hooftman
authors.forename: J
authors.initials: J
authors.lastname: Alsina
mesh_terms: D000208:Acute Disease; D000328:Adult; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013256:Steroids; D013375:Substance Withdrawal Syndrome
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids; D016572:Cyclosporine; D003404:Creatinine; D009173:Mycophenolic Acid